How much 'PrEP-resistant' HIV is out there?
Ibalizumab, active against highly resistant HIV, now approved in US
Statin users have lower rates of many types of cancer
The vaginal ring: more HOPE to the DREAM? Higher adherence and better effectiveness seen in open-label ring studies
Efavirenz may undermine effectiveness of the vaginal ring contraceptive
Average time from HIV diagnosis to treatment fell to six days in 2016 in San Francisco
Transgender women in Los Angeles are more likely to be in high HIV incidence clusters than any other group
PrEP use growing in US, but not reaching all those in need
Biktarvy combo maintains viral suppression after switching therapy
